Global Journal of Medical Research, I: Surgeries and Cardiovascular System, Volume 22 Issue 2

Traumatic Facial Injury Treated by Botulinum Toxin A 48 Year 2022 Global Journal of Medical Research Volume XXII Issue II Version I ( DDD ) I © 2022 Global Journals controlled, trial with clinical, skin reflectance, histological, immunohistochemical and biochemical evaluations. Acta DermVenereol, 2007; 87(1):27–32. Doi: 10.2340/00015555-0154. 9. Heppt MV., Breuninger H., Reinholz M., et al. Current strategies in the treatment of scars and keloids. Facial PlastSurg, 2015; 31(4):386-95. Doi: 10.1055/s-0035-1563694. 10. Arno AI., Gauglitz GG., Barret JP., et al. Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. Burns, 2014 ; 40(7): 1255- 1266. Doi: 10.1016/j.burns.2014.02.011. 11. Gauglitz GG. Management of keloids and hypertrophic scars: current and emerging options. ClinCosmetInvestigDermatol, 2013; 6: 103-114. Doi: 10.2147/CCID.S35252. 12. Kim YS., Lee HJ., Cho SH., et al. Early postoperative treatment of thyroidectomy scars using botulinum toxin: a split-scar, double-blind randomized controlled trial. Wound Repair Regen, 2014 ; 22(5): 605-612. Doi: 10.1111/wrr.12204. 13. Shaarawy E., Hegazy RA., Abdel Hay RM. Intralesionalbotulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial. J CosmetDermatol , 2015; 14(2): 161-166. Doi: 10.1111/jocd.12134. 14. Campanati A., Martina E., Giuliodori K., et al. Botulinum toxin off-label use in dermatology: a review. Skin Appendage Disord, 2017; 3(1): 39-56. Doi: 10.1159/000452341. 15. Fagien S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. PlastReconstrSurg, 1999; 103(2): 701–713. Doi: 10.1097/00006534-199902 000-00055. 16. Ziade M., Domergue S., Batifol D., et al. Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomized study. J PlastReconstrAesthetSurg, 2013; 66(2): 209–214. Doi: 10.1016/j.bjps.2012.09.012. 17. Chadwick S., Heath R., Shah M. Abnormal pigmentation within cutaneous scars: a complication of wound healing. Indian J PlastSurg, 2012; 45(2): 403–411. Doi: 10.4103/0970-0358. 101328. 18. Ortonne JP., Bissett DL. Latest insights into skin hyperpigmentation. J InvestigDermatolSympProc, 2008; 13: 10–14. Doi: 10.1038/jidsymp.2008.7. 19. Carmichael NM., Dostrovsky JO., Charlton MP. Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin, 2010; 149: 316–324. Doi: 10.1016/ j.pain.2010.02.024.